SLC5A2 and type 2 diabetes mellitus: Phlorizin was the lead compound that the pharmaceutical industry used to develop specific SGLT2 inhibitors, e.g., dapagliflozin (Forxiga®) and empagliflozin (Jardiance®), to treat type 2 diabetes mellitus [3, 15].